Alzamend Neuro 주가의 최고가, 최저가 및 변동 요약
과거 주가
현재 주가	US$1.75
52주 최고가	US$2.68
52주 최저가	US$0.84
베타	0.24
1개월 변동	12.90%
3개월 변동	36.72%
1년 변동	-25.53%
3년 변동	-99.43%
5년 변동	-99.90%
IPO 이후 변동	-99.90%

최근 뉴스 및 업데이트

Recent updates

새로운 내러티브 • Aug 16

Alzamend Neuro's Novel Lithium Formulation Will Target Major Mental Health Challenges

Catalysts AL001 : a novel lithium formulation targeting Alzheimer's disease, Bipolar Disorder, Major Depressive Disorder (MDD), and PTSD. Phase II studies show promising safety/efficacy, with trials ongoing as of 2025.

분석 기사 • Jul 26

Is Alzamend Neuro (NASDAQ:ALZN) In A Good Position To Deliver On Growth Plans?

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...

분석 기사 • Mar 20

Is Alzamend Neuro (NASDAQ:ALZN) In A Good Position To Deliver On Growth Plans?

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...

분석 기사 • Oct 14

We're Not Very Worried About Alzamend Neuro's (NASDAQ:ALZN) Cash Burn Rate

We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...

Seeking Alpha • Oct 05

Alzamend stock falls amid start of AL001 dosing in healthy people in Alzheimer's trial

Alzamend Neuro (NASDAQ:ALZN) said it began dosing healthy people in a phase 2A study of oral drug AL001 treat people with dementia related to Alzheimer’s. The placebo-controlled trial (AL001-02) started in May to evaluate the safety and tolerability of AL001 under multiple-dose setting, to determine the maximum tolerated dose, the company said in an Oct. 5 press release. Based on a recommendation by the U.S. Food and Drug Administration (FDA) after its review on Alzamend's pre-investigational new drug briefing package to develop AL001 for bipolar, major depressive and post-traumatic stress disorders, the ongoing clinical trial in Alzheimer's patients was expanded, the company added. ALZN -6.52% to $1.29 premarket Oct. 5

Seeking Alpha • Sep 29

Alzamend seeks FDA nod for early-stage trial of its therapy for Alzheimer’s type dementia

Clinical-stage biopharma Alzamend Neuro (NASDAQ:ALZN) on Thursday said it had submitted an investigational new drug (IND) application to the U.S. FDA for a phase 1/2A trial of its immunotherapy product candidate ALZN002 for the treatment of dementia of the Alzheimer's type. ALZN said the product candidate consists of dendritic cells, or activated white blood cells taken from an individual patients so that they can be engineered outside of the body to attack Alzheimer's-related amyloid-beta proteins. The purpose of the phase 1/2A trial would be to assess the safety, tolerability, and efficacy of multiple ascending doses of ALZN002 compared to placebo in 20‑30 subjects with mild to moderate dementia of the Alzheimer’s type, ALZN said in a statement. ALZN stock -1.7% to $1.16 in premarket trading. Shares of ALZN gained 6.3% on Wednesday, amidst a broader rally in drug companies that are working on Alzheimer's treatments sparked by positive data from Biogen (BIIB) and Eisai (OTCPK:ESALY).

Seeking Alpha • Jul 18

Alzamend Neuro receives positive pre-IND response from FDA for AL001

Alzamend Neuro (NASDAQ:ALZN) said on Monday it had received a written response to its meeting request relating to its Type B Pre-Investigational New Drug application from the U.S. Food and Drug Administration. The company said the FDA’s response provides a path for its planned clinical development of AL001 for the treatment of bipolar disorder, major depressive disorder and post-traumatic stress disorder. AL001 has the potential to deliver benefits of marketed lithium carbonate while avoiding current toxicities associated with lithium. Alzamend expects to file INDs for bipolar disorder, MDD and PTSD upon the completion of the current Phase IIA multiple ascending dose study.

Seeking Alpha • Dec 18

Alzamend: Biotech To Watch With 2 Drugs Targeting Multi-Billion Dollar Alzheimer's Market

Alzamend reported positive results from its phase 1 study using AL001 for the treatment of patients with Alzheimer's Disease. The phase 2 multiple ascending dose study using AL001 treating this patient population is expected to begin Q2 of 2022. AL002 is another shot on goal targeting Alzheimer's Disease and it is a cell therapy focused on boosting T-cell activity in the body to clear amyloid from the brain. It is estimated that the global market opportunity for Alzheimer's Disease could reach $25.5 billion by 2025.

주주 수익률

	ALZN	US Biotechs	US 시장
7D	5.4%	-3.9%	-1.5%
1Y	-25.5%	40.0%	13.3%

수익률 대 산업: ALZN은 지난 1년 동안 40%의 수익을 기록한 US Biotechs 산업보다 저조한 성과를 냈습니다.

수익률 대 시장: ALZN은 지난 1년 동안 13.3%를 기록한 US 시장보다 저조한 성과를 냈습니다.

주가 변동성

Is ALZN's price volatile compared to industry and market?
ALZN volatility
ALZN Average Weekly Movement	8.2%
Biotechs Industry Average Movement	9.5%
Market Average Movement	6.9%
10% most volatile stocks in US Market	15.3%
10% least volatile stocks in US Market	2.9%

안정적인 주가: ALZN는 지난 3개월 동안 US 시장에 비해 주가 변동성이 크지 않았습니다.

시간에 따른 변동성: ALZN의 주간 변동성(8%)은 지난 1년 동안 안정적이었습니다.

회사 소개

설립	직원 수	CEO	웹사이트
2016	5	Stephan Jackman	www.alzamend.com

임상 단계의 바이오제약 기업인 알자멘드 뉴로(Alzamend Neuro, Inc.)는 신경퇴행성 및 정신 질환 치료를 위한 다양한 제품 개발에 주력하고 있습니다. 이 회사의 파이프라인에는 알츠하이머병, 양극성 장애, 외상 후 스트레스 장애, 주요 우울 장애, 기타 신경퇴행성 질환 및 정신 질환 치료를 위해 리튬, 프롤린, 살리실레이트의 치료적 조합을 전달하는 AL001과, 또한 ALZN002는 돌연변이 펩타이드에 감작된 세포를 세포 기반 치료용 백신으로 활용하여, 환자의 면역 체계가 알츠하이머병에 대항할 수 있는 능력을 회복시키는 방법을 사용합니다. 알자멘드 뉴로(Alzamend Neuro, Inc.)는 2016년에 설립되었으며, 조지아주 애틀랜타에 본사를 두고 있습니다.

Alzamend Neuro, Inc. 기초 지표 요약

Alzamend Neuro의 순이익과 매출은 시가총액과 어떻게 비교됩니까?
ALZN 기초 통계
시가총액	US$8.24m
순이익 (TTM)	-US$9.10m
매출 (TTM)	n/a

0.0x

주가매출비율(P/S)

-0.9x

주가수익비율(P/E)

ALZN는 고평가되어 있습니까?

공정 가치 및 평가 분석 보기

순이익 및 매출

최근 실적 보고서(TTM)의 주요 수익성 지표
ALZN 손익계산서 (TTM)
매출	US$0
매출원가	US$0
총이익	US$0
기타 비용	US$9.10m
순이익	-US$9.10m

최근 보고된 실적

Jul 31, 2026

다음 실적 발표일

해당 없음

주당순이익(EPS)	-1.90
총이익률	0.00%
순이익률	0.00%
부채/자본 비율	0%

ALZN의 장기 실적은 어땠습니까?

과거 실적 및 비교 보기

기업 분석 및 재무 데이터 상태

데이터	최종 업데이트 (UTC 시간)
기업 분석	2026/09/14 17:14
종가	2026/09/14 00:00
수익	2026/07/31
연간 수익	2026/04/30

데이터 소스

당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.

패키지	데이터	기간	미국 소스 예시 ^*
기업 재무제표	10년	손익계산서 현금흐름표 대차대조표	SEC 양식 10-K SEC 양식 10-Q
분석가 컨센서스 추정치	+3년	재무 예측 분석가 목표주가	분석가 리서치 보고서 Blue Matrix
시장 가격	30년	주가 배당, 분할 및 기타 조치	ICE 시장 데이터 SEC 양식 S-1
지분 구조	10년	주요 주주 내부자 거래	SEC 양식 4 SEC 양식 13D
경영진	10년	리더십 팀 이사회	SEC 양식 10-K SEC 양식 DEF 14A
주요 개발	10년	회사 공시	SEC 양식 8-K

^* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.

별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.

분석 모델 및 스노우플레이크

이 보고서를 생성하는 데 사용된 분석 모델의 세부 정보는 당사의 GitHub 페이지에서 확인하실 수 있습니다. 또한 보고서 사용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.

Simply Wall St 분석 모델을 설계하고 구축한 에 대해 알아보세요.

산업 및 섹터 지표

산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.

분석가 소스

Alzamend Neuro, Inc.는 1명의 분석가가 다루고 있습니다. 이 중 1명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.

분석가	기관
Edward Woo	Ascendiant Capital Markets LLC

Alzamend Neuro (ALZN) 주식 개요

위험 분석

Top Community Narratives

Alzamend Neuro's Novel Lithium Formulation Will Target Major Mental Health Challenges

Top Community Narratives

Alzamend Neuro's Novel Lithium Formulation Will Target Major Mental Health Challenges

Alzamend Neuro, Inc. 경쟁사

Imunon

Soligenix

Exicure

Acurx Pharmaceuticals

가격 이력 및 성과

최근 뉴스 및 업데이트

Alzamend Neuro Reports Resting-State Fmri Findings For Al001 Accepted For Poster Presentation At Neuroscience 2026

New major risk - Revenue and earnings growth

Alzamend Neuro, Inc. Reports Phase 1/2A Lithium Imaging Data For AL001 At ISMRM Workshop

New major risk - Financial position

Alzamend Neuro, Inc. Announces Demise of Lynne Fahey Mcgrath, Director on July 20, 2026

Alzamend Neuro, Inc. Reports Encouraging Pharmacodynamic Data From Phase II Clinical Trial Of AL001

Recent updates

Alzamend Neuro Reports Resting-State Fmri Findings For Al001 Accepted For Poster Presentation At Neuroscience 2026

New major risk - Revenue and earnings growth

Alzamend Neuro, Inc. Reports Phase 1/2A Lithium Imaging Data For AL001 At ISMRM Workshop

New major risk - Financial position

Alzamend Neuro, Inc. Announces Demise of Lynne Fahey Mcgrath, Director on July 20, 2026

Alzamend Neuro, Inc. Reports Encouraging Pharmacodynamic Data From Phase II Clinical Trial Of AL001

Price target decreased by 33% to US$28.00

Alzamend Neuro, Inc. Reports Positive Topline Data From Phase II Clinical Trial of AL001

Alzamend Neuro, Inc. Receives Nasdaq Notice Regarding Non-Compliance with Continued Listing Rule

Alzamend Neuro Initiates Phase Ii Clinical Trial of Al001 Lithium in Brain Study in Patients with Bipolar Disorder in Collaboration with Massachusetts General Hospital

Alzamend Neuro, Inc., Annual General Meeting, Apr 17, 2026

Alzamend Neuro, Inc. Announces Completion of Clinical Portion of Phase II Clinical Trial of AL001 Lithium in Brain Study Conducted at Massachusetts General Hospital

Alzamend Neuro's Novel Lithium Formulation Will Target Major Mental Health Challenges

Alzamend Neuro, Inc. Announces Dosing of First Patient in its Phase II Clinical Trial of AL001 "Lithium in Brain" Study Taking Place at Massachusetts General Hospital

Alzamend Neuro Enrolls First Patient in its Phase II Clinical Trial of AL001 "Lithium in Brain" Study Taking Place at Massachusetts General Hospital

Alzamend Neuro, Inc. Initiates First Phase II Clinical Trial of AL001 "Lithium in Brain" Study Taking Place at Massachusetts General Hospital

Alzamend Neuro Announces Initiation Date of Phase II Clinical Trial of Al001 for Treatment of Major Depressive Disorder to Take Place At Massachusetts General Hospital

Alzamend Neuro Announces Initiation Date of Phase II Clinical Trial of AL001 for Treatment of Post-Traumatic Stress Disorder to Take Place at Massachusetts General Hospital

Alzamend Neuro Announces Initiation Date of Phase Ii Clinical Trial of Al001 for Treatment of Bipolar Disorder to Take Place At Massachusetts General Hospital

Alzamend Neuro, Inc., Annual General Meeting, Apr 25, 2025

Alzamend Neuro, Inc. announced that it expects to receive $5 million in funding

Alzamend Neuro, Inc. Announces Initiation Date of First Phase II Clinical Trial of AL001 to Take Place At Massachusetts General Hospital

Alzamend Neuro, Inc. Announces Completion of a Novel Head Coil by Tesla for Measuring Brain Structure Lithium Levels in Five Upcoming Phase II Clinical Trials at Massachusetts General Hospital

Alzamend Neuro, Inc. Announces Full Data Set from Its Nonclinical Study: Comparing Brain and Plasma Lithium Carbonate in Alzheimer's Transgenic Mice

Alzamend Neuro, Inc. Announces Full Data Set from Phase IIA Multiple Ascending Dose Clinical Trial for AL001 Treatment of Dementia Related to Alzheimer's

Alzamend Neuro, Inc. has filed a Follow-on Equity Offering in the amount of $6.5 million.

Alzamend Neuro Regains Compliance with Nasdaq's Minimum Bid Price Requirement

Alzamend Neuro, Inc. announced that it expects to receive $25 million in funding

Alzamend Neuro, Inc. has completed a Follow-on Equity Offering in the amount of $1.3 million.

Alzamend Neuro, Inc., Annual General Meeting, May 13, 2024

The Nasdaq Stock Market LLC Determines Alzamend Neuro's Common Stock to be Scheduled for Delisting from The Nasdaq Capital Market and to be Suspended at the Opening of Business on April 4, 2024

Alzamend Neuro, Inc., Annual General Meeting, Apr 30, 2024

Alzamend Neuro, Inc. announced delayed 10-Q filing

Alzamend Neuro, Inc. Appoints Milton C. Ault, III as a Director and Vice Chairman

Price target decreased by 67% to US$20.00

New major risk - Revenue and earnings growth

Alzamend Neuro, Inc. Receives FDA " Study May Proceed" Notification for A Phase IIA Clinical Trial of Al001, A Next-Generation Lithium Therapeutic Drug Candidate, in Post-Traumatic Stress Disorder Patients

Alzamend Neuro Receives FDA " Study May Proceed" Notification for A Phase IIA Clinical Trial of Al001, A Next-Generation Lithium Therapeutic Drug Candidate, in Major Depressive Disorder Patients

Alzamend Neuro Regains Compliance with Nasdaq’s Minimum Bid Price Requirement

Alzamend Neuro, Inc. Submits IND Application for A Phase IIa Clinical Trial in Post-Traumatic Stress Disorder Patients of Next-Generation Lithium Therapeutic Drug Candidate AL001

New major risk - Market cap size

New major risk - Share price stability

Alzamend Neuro, Inc. Submits Investigational New Drug Application for A Phase IIA Clinical Trial in Major Depressive Disorder Patients of Its Next-Generation Lithium Therapeutic Drug Candidate AL001

Price target increased by 58% to US$6.50

Alzamend Neuro, Inc Receives FDA “Study May Proceed” Notification for a Phase IIA Clinical Trial of AL001, a Next-Generation Lithium Therapeutic Drug Candidate, in Bipolar Disorder Patients

Alzamend Neuro Receives Non-Compliance Notice From Nasdaq

Alzamend Neuro Receives Extension by Nasdaq Panel to Regain Compliance with the Minimum Bid Price Continued Listing Requirement

New major risk - Negative shareholders equity

Alzamend Neuro Receives Notification from Nasdaq Regarding Not Eligible for Second 180 Day Compliance Period

Is Alzamend Neuro (NASDAQ:ALZN) In A Good Position To Deliver On Growth Plans?

Alzamend N Neuro, Inc. Announces Positive Phase IIA Clinical Trial Results for AL001

Price target decreased by 41% to US$4.13

Is Alzamend Neuro (NASDAQ:ALZN) In A Good Position To Deliver On Growth Plans?

Price target decreased to US$7.25

High number of new and inexperienced directors

Price target decreased to US$7.25

We're Not Very Worried About Alzamend Neuro's (NASDAQ:ALZN) Cash Burn Rate

Alzamend stock falls amid start of AL001 dosing in healthy people in Alzheimer's trial

Alzamend seeks FDA nod for early-stage trial of its therapy for Alzheimer’s type dementia

Price target increased to US$15.00